Inside A Bold New Approach To Alzheimer’s

Key Concepts

Alzheimer's disease, neurocognitive decline, synapse regeneration, small molecule drugs, clinical trials (Phase 1, Phase 2, Phase 3), amyloid plaques, neurodegenerative diseases, neuropsychiatric diseases, ALS (Amyotrophic Lateral Sclerosis), fragile X syndrome, orphan disease designation, fast track designation, compassionate use, NDA (New Drug Application), blood-brain barrier, patient compliance, heterogeneous diseases, combination therapy.

Main Topics and Key Points

Introduction

• 7 million Americans have Alzheimer's disease, and this number is expected to double in the next 25 years.
• Women are more likely to experience neurocognitive decline than men.
• Stella Saraf, founder and CEO of Spinogenics, aims to reverse neurocognitive decline through synaptic regeneration.

Spinogenics' Approach to Treating Brain Diseases

• Spinogenics focuses on synaptic regeneration to combat brain diseases, including Alzheimer's.
• Synapses are fundamental for neuronal communication, affecting planning, thinking, movement, sight, and breathing.
• The company is developing small molecule drugs to restore synapses and regain function, with the goal of restoring memory and cognitive abilities.
• Spinogenics is currently in Phase 2 clinical trials.
• Example: The company's website features a before-and-after image of GGI staining in an animal, showing increased synapses after treatment.

Synaptic Regeneration vs. Targeting Plaques

• While some treatments target amyloid plaques, Spinogenics takes a different approach by focusing on synaptic regeneration.
• The rationale is that many brain conditions, including neurodegenerative and neuropsychiatric diseases, originate in the brain, where synapses are fundamental.
• Synapses decline over time due to disease pathology, and Spinogenics aims to restore them.
• Stella Saraf, as a chemist, pursued this "out-of-the-box" idea and built connections with collaborators to conduct animal studies and progress to clinical trials.

Clinical Trial Phases and Progress

• Drug development is a "marathon" that starts with bench research, followed by cell and animal studies.
• Animal studies focus on safety and efficacy before moving to human trials.
• Phase 1: Human safety trials.
• Phase 2: Assessing dosage and efficacy in humans. Spinogenics is currently conducting Phase 2 trials for Alzheimer's, ALS, and schizophrenia.
• Spinogenics also has a program for fragile X syndrome (under the autism spectrum) that uses a synaptic corrective mechanism.
• The company has a clinical trial in Australia and FDA fast-track grants for fragile X.
• The geographic diversity in trials is intentional, leveraging Australia's efficiency in Phase 1 trials.
• SPG302 for ALS has IND clearance from the FDA to start trials in the United States.
• The company aims to provide access to the drug to as many patients as possible through compassionate use programs.

Orphan Disease Designation and Future Phases

• Phase 3: Follows Phase 2, and successful completion can lead to an NDA (New Drug Application) for market approval.
• Orphan disease designations (like for ALS and fragile X) allow for more communication with the FDA to expedite the process.

Applicability of Synaptic Approach to Other Diseases

• Synapses are fundamental in many diseases beyond those currently targeted by Spinogenics.
• Potential applications include frontotemporal dementia and Parkinson's disease.
• The company is limited by resources but acknowledges the broad applicability of their approach.
• Spinogenics is "drugging known biology," meaning they are targeting well-understood biological processes.
• The use of small molecule drugs is crucial for patient compliance, ease of administration (oral pill vs. infusion), and potential benefits to the healthcare system.
• The company's approach is a "new zip code" in treatment, complementing existing therapies.
• The drug has shown good safety and tolerability, which is important for larger trials.
• Existing memory drugs often have significant gastrointestinal side effects, which Spinogenics hopes to avoid.

Impact of Macro Environment and Grant Funding

• Grant funding is critical for innovation, especially for early-stage companies like Spinogenics.
• The company benefited from NIH and DoD grants for animal studies.
• Cuts in grant funding at academic institutions and agencies like the CDC and NIH can hinder innovation.

Stella Saraf's Background and Motivation

• Stella Saraf's personal experiences with her parents' health battles (Parkinson's and oncology) motivated her to start Spinogenics.
• Her father's Parkinson's diagnosis, specifically the irreversible brain damage present by the time symptoms manifest, inspired her to find ways to detect and treat diseases earlier.
• Her first company focused on early disease detection, but investors were hesitant due to the lack of treatments for diseases like Alzheimer's.
• This led her to found Spinogenics, driven by the frustration that neurology was "decades behind" oncology in terms of treatment options.
• Her background in big pharma and venture capital (VC) helped her build the company strategically, derisking each step.

Venture Capital Experience and Fundraising

• Stella Saraf's 10+ years in VC were invaluable for understanding financing and building companies.
• She emphasizes the importance of creative planning and derisking to reach patients quickly.
• Her VC connections have been helpful for fundraising, but she acknowledges the challenges of financing, regulation, and disease heterogeneity.
• She always has multiple plans (A, B, C, D) to navigate these challenges.

The Role of Chemistry in Building Spinogenics

• Having a PhD and being a chemist has helped Stella Saraf with problem-solving and quick iteration.
• However, the success of Spinogenics is attributed to its integrated team, including biologists and regulatory experts, who bring diverse perspectives.

Current Challenges and Misconceptions

• Stella Saraf's biggest challenge is the responsibility she feels towards patients on the waiting list.
• She is constantly seeking ways to expedite the process and help more patients.
• The biggest misconception about neurodegenerative diseases is the expectation of a single "cure."
• Neurology is still in its early stages compared to oncology, and combination therapies are likely needed.
• Diseases like Alzheimer's and ALS are highly heterogeneous, with various subtypes, requiring personalized treatment approaches.
• Spinogenics aims to catalyze more research in synaptic regeneration and push the boundaries of treatment beyond just slowing progression.

Future Goals (Spring 2026)

• The goal is to be actively treating patients and advancing clinical trials.
• The company hopes to be in communication with regulatory authorities and expanding treatment access.

Notable Quotes

• "Drug development is a marathon."
• "We are drugging known biology."
• "Neurology was where oncology was decades ago."
• "I have a no regrets, let's just try, let's do what we can to understand it."

Technical Terms and Concepts

• Synapses: The connections between neurons that allow them to communicate.
• Small Molecule Drug: An organic compound with a low molecular weight, typically administered orally.
• Amyloid Plaques: Abnormal protein deposits in the brain associated with Alzheimer's disease.
• Neurodegenerative Diseases: Diseases characterized by the progressive loss of structure or function of neurons.
• Neuropsychiatric Diseases: Mental disorders caused by diseases of the nervous system.
• ALS (Amyotrophic Lateral Sclerosis): A progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
• Fragile X Syndrome: A genetic disorder that causes intellectual disability, developmental delays, and behavioral and learning challenges.
• Orphan Disease Designation: A status assigned to a drug intended to treat a rare disease, providing incentives for development.
• Fast Track Designation: A process designed to expedite the review of drugs to treat serious conditions and fill an unmet medical need.
• Compassionate Use: Allowing patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials.
• NDA (New Drug Application): The application submitted to the FDA to request approval for a new drug to be sold in the United States.
• Blood-Brain Barrier: A protective barrier that restricts the passage of substances from the bloodstream into the brain.
• Heterogeneous Diseases: Diseases that vary in their presentation, progression, and response to treatment.
• Combination Therapy: The use of multiple drugs or treatments to address a disease.
• IND (Investigational New Drug): A request for FDA authorization to administer an investigational drug or biological product to humans.
• GGI Staining: A staining technique used to visualize synapses.

Logical Connections

The interview begins by establishing the problem of Alzheimer's and neurocognitive decline. It then introduces Spinogenics and its approach to synaptic regeneration as a potential solution. The discussion progresses through the scientific rationale behind this approach, the stages of clinical trials, and the applicability of the technology to various diseases. Stella Saraf's personal motivation and background in VC are explored, highlighting the strategic approach to building the company. The interview concludes with a discussion of current challenges, misconceptions about neurodegenerative diseases, and future goals for Spinogenics.

Data, Research Findings, or Statistics

• 7 million Americans have Alzheimer's disease.
• The number of Alzheimer's cases is expected to double in the next 25 years.

Synthesis/Conclusion

Spinogenics is pioneering a novel approach to treating neurodegenerative diseases by focusing on synaptic regeneration. Led by Stella Saraf, the company is currently in Phase 2 clinical trials with promising results. Their small molecule drug aims to restore cognitive function and improve the quality of life for patients with Alzheimer's, ALS, schizophrenia, and fragile X syndrome. While challenges remain in drug development and funding, Spinogenics is committed to pushing the boundaries of treatment and addressing the unmet needs of patients with these debilitating conditions. The company's innovative approach, combined with a strong team and strategic planning, positions them as a potential leader in the field of synaptic regeneration.